Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450808 | 0.91 | TAS2R14 (0.37) | ALDH1A1MAPTRAB9AL3MBTL1 | |
| SCHEMBL6077334 | 0.90 | POLB (0.34) | ALDH1A1MAPTTRPM8L3MBTL1 | |
| SCHEMBL6879078 | 0.90 | POLB (0.34) | ALDH1A1MAPTTRPM8L3MBTL1 | |
| SCHEMBL6077512 | 0.89 | ALDH1A1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL6078978 | 0.89 | BCL2A1 (0.37) | ALDH1A1MAPTRAB9A | |
| SCHEMBL6078972 | 0.89 | BCL2A1 (0.37) | ALDH1A1MAPTRAB9A | |
| SCHEMBL6077491 | 0.89 | ALDH1A1 (0.44) | NPSR1ALDH1A1MAPTTRPM8L3MBTL1 | |
| SCHEMBL6877621 | 0.89 | ALDH1A1 (0.44) | NPSR1ALDH1A1MAPTTRPM8L3MBTL1 | |
| SCHEMBL6077514 | 0.89 | ALDH1A1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL6871159 | 0.88 | NPSR1 (0.35) | NPSR1ALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467695-A2 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
| WO-2003049690-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | NPSR1 4477/4885ALDH1A1 976/4885CYP1A2 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.